| Literature DB >> 30703432 |
Yuan Cheng1, Xue-Lei Ma1, Yu-Quan Wei1, Xia-Wei Wei2.
Abstract
The chemokine receptor CXCR2 and its ligands are implicated in the progression of tumours and various inflammatory diseases. Activation of the CXCLs/CXCR2 axis activates multiple signalling pathways, including the PI3K, p38/ERK, and JAK pathways, and regulates cell survival and migration. The CXCLs/CXCR2 axis plays a vital role in the tumour microenvironment and in recruiting neutrophils to inflammatory sites. Extensive infiltration of neutrophils during chronic inflammation is one of the most important pathogenic factors in various inflammatory diseases. Chronic inflammation is considered to be closely correlated with initiation of cancer. In addition, immunosuppressive effects of myeloid-derived suppressor cells (MDSCs) against T cells attenuate the anti-tumour effects of T cells and promote tumour invasion and metastasis. Over the last several decades, many therapeutic strategies targeting CXCR2 have shown promising results and entered clinical trials. In this review, we focus on the features and functions of the CXCLs/CXCR2 axis and highlight its role in cancer and inflammatory diseases. We also discuss its potential use in targeted therapies.Entities:
Keywords: CXC chemokine receptor 2; CXC chemokines; Cancer; Inflammation; Targeted therapy
Mesh：
Substances：
Year: 2019 PMID： 30703432 DOI： 10.1016/j.bbcan.2019.01.005
Source DB: PubMed Journal: Biochim Biophys Acta Rev Cancer ISSN： 0304-419X Impact factor: 10.680